01—Abstract
Summary
Summary of the 8-K filed December 23, 2020. Cited figures are marked; the original filing is the authoritative source.
Moderna, Inc. (MRNA) announced on December 23, 2020, a significant update regarding its executive and board trading policies.
Previously, senior leadership had voluntarily agreed not to engage in new stock trading plans or add to existing ones until the FDA filed a Biologics License Application (BLA) for its COVID-19 vaccine, or until the program was discontinued. This restriction was put in place following an August 2020 disclosure.
Following the U.S. Food and Drug Administration's (FDA) issuance of an Emergency Use Authorization (EUA) for the Moderna COVID-19 Vaccine on December 18, 2020, coupled with positive recommendations and the initiation of U.S. distribution on December 20, 2020, the company has now lifted these trading restrictions. Members of the executive committee and board of directors are now permitted to trade Moderna stock through new or amended 10b5-1 plans, adhering to the company's standard policies.
02—Key points
Key Highlights
- Moderna's executive and board members can now resume trading Moderna stock.
- The lifting of trading restrictions is a direct result of the FDA granting an Emergency Use Authorization (EUA) for the Moderna COVID-19 Vaccine.
- This development follows the FDA's EUA on December 18, 2020, and the CDC's favorable recommendation and initiation of U.S. distribution on December 19-20, 2020.
- Previously, senior leadership had voluntarily restricted new stock trades and additions to existing plans.
- The prior trading restriction was tied to the filing of a Biologics License Application (BLA) or discontinuation of the vaccine program.
- Future trades will be conducted under new or amended 10b5-1 plans in accordance with company policies.
- This announcement is considered Regulation FD Disclosure and is not deemed 'filed' for certain SEC purposes.
03—Questions
Frequently Asked Questions
What is the main news from this 8-K filing?
The main news is that Moderna's executive committee and board of directors are now permitted to resume trading in Moderna stock. This follows the lifting of a voluntary trading restriction they had previously agreed to.
Why were the trading restrictions put in place?
The restrictions were put in place in August 2020, as a voluntary measure, until the earlier of the FDA filing a Biologics License Application (BLA) for the COVID-19 vaccine or the discontinuation of the vaccine development program. This was to ensure transparency and avoid potential concerns about insider trading during a critical development phase.
What event triggered the lifting of these trading restrictions?
The primary trigger was the U.S. Food and Drug Administration (FDA) granting an Emergency Use Authorization (EUA) for the Moderna COVID-19 Vaccine on December 18, 2020. This was followed by a favorable recommendation from the CDC's advisory committee and the commencement of U.S. vaccine distribution.
Are there any limitations on the new stock trades?
While the restrictions are lifted, trades will now be conducted through new or amended 10b5-1 trading plans in the ordinary course, in accordance with Moderna's established policies and procedures. The company has not undertaken any obligation to provide further updates on this matter.
04—Continue